Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin

Cancer Chemotherapy and Pharmacology
J CassidyS B Kaye

Abstract

Our previous randomised trial in patients with advanced ovarian cancer indicated a significant response and survival advantage for those receiving high-dose (100 mg/m2) as compared with low-dose (50 mg/m2) cisplatin in combination with cyclophosphamide (750 mg/m2). However, this was accompanied by more toxicity; peripheral neuropathy was troublesome, with 32% of patients experiencing > or = WHO grade 2 at the cisplatin dose of 100 mg/m2. Nimodipine is a calcium-channel antagonist that has provided protection from cisplatin-induced neurotoxicity in a rat model system. We performed a pilot study in 50 patients that demonstrated the feasibility of co-administration of nimodipine in a chronic oral dosing schedule with cisplatin-based chemotherapy in an open-label non-randomised trial. This led us to initiate a double-blind, placebo-controlled, randomised trial in patients with ovarian cancer, which was prematurely discontinued because of problems with nausea and vomiting, leading to poor patient compliance, that were not predicted by the pilot study. These studies did not demonstrate a neuroprotective effect for nimodipine. The primary efficacy variable, i.e, the neurotoxicity score at the end of treatment, gave a significantly low...Continue Reading

Citations

Jul 2, 2003·Toxicology and Applied Pharmacology·G BárdosP Literáti-Nagy
Jan 8, 2000·Journal of Inorganic Biochemistry·D Screnci, M J McKeage
Aug 13, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M BaconB Zee
Nov 18, 2004·Journal of the National Cancer Institute·Paul A VaseyUNKNOWN Scottish Gynaecological Cancer Trials Group
Dec 11, 2008·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Nicolas TsavarisChristos Koufos
Apr 16, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dawn L HershmanCharles L Loprinzi
Nov 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H MooreUNKNOWN Gynecologic Oncology Group
Jun 24, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sherry WolfCharles Loprinzi
Mar 14, 2017·Journal of Integrative Medicine·Marco Cascella, Maria Rosaria Muzio
Apr 2, 2014·The Cochrane Database of Systematic Reviews·James W AlbersRoss C Donehower
Feb 7, 2007·American Journal of Clinical Oncology·Melanie Walker, Oliver Ni
Jan 16, 2009·Basic & Clinical Pharmacology & Toxicology·Henrik GréenCurt Peterson
Feb 17, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Gerardo Gutiérrez-GutiérrezEduardo Gutiérrez-Rivas
Mar 15, 2015·The Oncologist·Abolfazl AvanGodefridus J Peters
Mar 3, 2020·Journal of Pain & Palliative Care Pharmacotherapy·Rishi KachraniJayne Pawasauskas
Dec 31, 2010·Current Treatment Options in Neurology·Guido CavalettiEmanuela Susani
Jul 2, 2020·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Terry TrinhArun V Krishnan
Sep 29, 2019·Current Neuropharmacology·Andrew P CarlsonClaude W Shuttleworth
Sep 5, 2017·Expert Review of Anticancer Therapy·Marios Bakogeorgos, Vassilis Georgoulias
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A VaseyS B Kaye
Feb 20, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Béatrice WeberUNKNOWN GINECO group, France
Jun 19, 2001·Cancer Investigation·M Corbo, C Balmaceda
Nov 11, 2003·The Journal of Nutrition·Edwin Rock, Angela DeMichele
Jul 3, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David Kudlowitz, Franco Muggia
Jan 14, 2021·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Sultan Aydin KökerRaziye Canan Vergin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.